20
Selecting a Treatment Regimen
Table 7b. HIV Drugs (continued)
Drug Name Formulations Dosing Recommendations
a
Characteristics of Protease Inhibitors (PIs) (continued)
Lopinavir/ritonavir
(LPV/r)
Kaletra
®
Tablets:
(Take without
regard to meals)
• LPV 200 mg +
RTV 50 mg, or
• LPV 100 mg +
RTV 25 mg
Oral Solution:
(Take with food)
• Each 5 mL
contains (LPV
400 mg + RTV
100 mg )
• Oral solution
contains 42%
alcohol.
• LPV/r 400 mg/100 mg bid or LPV/r
800 mg/200 mg once daily
• Once-daily dosing is not recommended
for patients with ≥3 LPV-associated
mutations, pregnant women, or
patients receiving EFV, NVP, FPV,
NFV, carbamazepine, phenytoin, or
phenobarbital.
With EFV or NVP (PI- Naive or PI-
Experienced Patients):
• LPV/r 500 mg/125 mg bid (use a
combination of 2 LPV/r 200 mg/50 mg
tablets + 1 LPV/r 100 mg/25 mg tablet
to make a total dose of LPV/r
500 mg/125 mg ), or
• LPV/r 533 mg/133 mg oral solution bid
Drug Name Formulations Dosing Recommendations
a
Characteristics of Integrase Inhibitors
Dolutegravir (DTG)
Tivicay
®
50 mg tablets Adults: 50 mg once daily
a
Children and Adolescents:
≥12 years and ≥40 kg: 50 mg once daily
a
Elvitegravir (EVG)
Available only as
Stribild
®
Tablets:
FTC 200 mg +
TDF 300 mg +
EVG 150 mg +
COBI 150 mg
Adults: One tablet once daily with food
Raltegravir (RAL)
Isentress
®
400 mg tablets
Chewable tablets
100 mg scored and
25 mg
Adults: 400 mg bid
With rifampin: 800 mg bid
Children and Adolescents:
≥12 years: 400 mg bid
2-11 years & ≥10 kg
d
: weight based
a
Max: 300 mg bid
▶ Take without regard to meals
Characteristics of Non-Antiretroviral Pharmacoenhancers
Cobicistat
(COBI)
Available only as
Stribild
®
• FTC 200 mg +
• TDF 300 mg +
• EVG 150 mg +
• COBI 150 mg
Adults: One tablet once daily with food
a
For dosage adjustment in hepatic insufficiency, see Table 4.
b
Rare cases of Stevens-Johnson syndrome have been reported with most NNRTIs. e highest
incidence of rash was seen with NVP.
